Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue: 2010-2018

Historic Non-Current Deffered Revenue for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Dec 2018 value amounting to $6.3 million.

  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue rose 15.76% to $6.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.3 million, marking a year-over-year increase of 15.76%. This contributed to the annual value of $6.3 million for FY2018, which is 15.76% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non-Current Deffered Revenue of $6.3 million as of Q4 2018, which was up 3.19% from $6.1 million recorded in Q3 2018.
  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $10.5 million during Q4 2014, with a 5-year trough of $557,000 in Q4 2016.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $5.0 million (2017), whereas its average is $4.6 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Non-Current Deffered Revenue plummeted by 91.29% in 2016 and then skyrocketed by 878.28% in 2017.
  • Ironwood Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $10.5 million in 2014, then slumped by 39.22% to $6.4 million in 2015, then tumbled by 91.29% to $557,000 in 2016, then surged by 878.28% to $5.4 million in 2017, then grew by 15.76% to $6.3 million in 2018.
  • Its last three reported values are $6.3 million in Q4 2018, $6.1 million for Q3 2018, and $6.1 million during Q2 2018.